These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16129367)

  • 1. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials.
    Di Maio M; Gridelli C; Gallo C; Shepherd F; Piantedosi FV; Cigolari S; Manzione L; Illiano A; Barbera S; Robbiati SF; Frontini L; Piazza E; Ianniello GP; Veltri E; Castiglione F; Rosetti F; Gebbia V; Seymour L; Chiodini P; Perrone F
    Lancet Oncol; 2005 Sep; 6(9):669-77. PubMed ID: 16129367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan.
    Chen YM; Perng RP; Shih JF; Tsai CM; Whang-Peng J
    Lung Cancer; 2007 Jun; 56(3):363-9. PubMed ID: 17306906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer?
    Maione P; Rossi A; Di Maio M; Gridelli C
    Lung Cancer; 2009 Oct; 66(1):8-14. PubMed ID: 19328587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
    Iranzo V; Sirera R; Bremnes RM; Blasco A; Jantus-Lewintre E; Tarón M; Berrocal A; Blasco S; Caballero C; Del Pozo N; Rosell R; Camps C
    Clin Lung Cancer; 2011 Jul; 12(4):224-30. PubMed ID: 21726821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials.
    Gargiulo P; Arenare L; Gridelli C; Morabito A; Ciardiello F; Gebbia V; Maione P; Spagnuolo A; Palumbo G; Esposito G; Della Corte CM; Morgillo F; Mancuso G; Di Liello R; Gravina A; Schettino C; Di Maio M; Gallo C; Perrone F; Piccirillo MC
    BMC Cancer; 2021 May; 21(1):549. PubMed ID: 33985435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of a biweekly regimen of vinorelbine and cisplatin in advanced non-small cell lung cancer.
    Chen CH; Lin CM; Kao KC; Chang JW; Tsao TC
    Chang Gung Med J; 2007; 30(3):249-55. PubMed ID: 17760276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
    Gatzemeier U; von Pawel J; Vynnychenko I; Zatloukal P; de Marinis F; Eberhardt WE; Paz-Ares L; Schumacher KM; Goddemeier T; O'Byrne KJ; Pirker R
    Lancet Oncol; 2011 Jan; 12(1):30-7. PubMed ID: 21169060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
    Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
    Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of the combination of vinorelbine and cisplatin in advanced non-small-cell lung cancer.
    Mori K; Kamiyama Y; Kondo T; Kano Y; Tominaga K
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):129-32. PubMed ID: 14605861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z
    Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03.
    Kishida Y; Kawahara M; Teramukai S; Kubota K; Komuta K; Minato K; Mio T; Fujita Y; Yonei T; Nakano K; Tsuboi M; Shibata K; Atagi S; Kawaguchi T; Furuse K; Fukushima M
    Br J Cancer; 2009 Nov; 101(9):1537-42. PubMed ID: 19862000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
    Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
    Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly.
    Chen YM; Perng RP; Shih JF; Whang-Peng J
    Lung Cancer; 2008 Aug; 61(2):214-9. PubMed ID: 18243407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of the risk factors for severe neutropenia in advanced non-small cell lung cancer after the first course of chemotherapy with third-generation agents].
    Shibuya M; Kogo M; Kurihara T; Shikama Y; Nakajima H; Yoneyama K; Kiuchi Y
    Yakugaku Zasshi; 2013; 133(6):703-9. PubMed ID: 23728094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer.
    Cao X; Ganti AK; Stinchcombe T; Wong ML; Ho JC; Shen C; Liu Y; Crawford J; Pang H; Wang X
    Lung Cancer; 2020 Mar; 141():14-20. PubMed ID: 31926983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel.
    Shitara K; Matsuo K; Takahari D; Yokota T; Shibata T; Ura T; Ito S; Sawaki A; Tajika M; Kawai H; Muro K
    Ann Oncol; 2010 Dec; 21(12):2403-2409. PubMed ID: 20494962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreated baseline neutrophil count and chemotherapy-induced neutropenia may be conveniently available as prognostic biomarkers in advanced gastric cancer.
    Chen Z; Chen W; Wang J; Zhu M; Zhuang Z
    Intern Med J; 2015 Aug; 45(8):854-9. PubMed ID: 25871806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.
    Ferrarotto R; Anderson I; Medgyasszay B; García-Campelo MR; Edenfield W; Feinstein TM; Johnson JM; Kalmadi S; Lammers PE; Sanchez-Hernandez A; Pritchett Y; Morris SR; Malik RK; Csőszi T
    Cancer Med; 2021 Sep; 10(17):5748-5756. PubMed ID: 34405547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.